Results 141 to 150 of about 1,500,628 (349)

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Assessing afebrile malaria and bed-net use in a high-burden region of India: Findings from multiple rounds of mass screening. [PDF]

PLoS One, 2023
Garg S, Gupta V, Patel K, Dewangan M, Nanda P, Sridhar R, Singh G.   +6 more
europepmc   +1 more source

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source

Selective screening for cervical cancer. Experience of the Finnish mass screening system. [PDF]

, 1977
Matti Hakama, ­Eero Pukkala
openalex   +1 more source

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

Molecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte, Osheen Sharma, Laura Leuenberger, Emelie Wallin, Josefin Fernebro, Päivi Östling, Rebecka Bergström, Johan Lindberg, Ulrika Joneborg, Olli Kallioniemi, Brinton Seashore‐Ludlow   +10 more
wiley   +1 more source

Estimating the long-term effects of mass screening for latent and active tuberculosis in the Marshall Islands. [PDF]

Int J Epidemiol, 2022
Ragonnet R, Williams BM, Largen A, Nasa J, Jack T, Langinlur MK, Ko E, Rahevar K, Islam T, Denholm JT, Marais BJ, Marks GB, McBryde ES, Trauer JM.   +13 more
europepmc   +1 more source

Studies on the Screening Mass Examination of Urine (Protein and Sugar in Urine) in a Farm-region (Naguri Villag., Iruma Distr., Saitama Prefect.)

, 1958
Fumiyoshi Yanagisawa, Makoto Sakaki, Morio Morozumi, Masuo Watanabe, Kimiko YANAGISAWA   +4 more
openalex   +2 more sources

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

A machine learning COVID-19 mass screening based on symptoms and a simple olfactory test. [PDF]

Sci Rep, 2022
Azeli Y, Fernández A, Capriles F, Rojewski W, Lopez-Madrid V, Sabaté-Lissner D, Serrano RM, Rey-Reñones C, Civit M, Casellas J, El Ouahabi-El Ouahabi A, Foglia-Fernández M, Sarrá S, Llobet E.   +13 more
europepmc   +1 more source

Dextrostix estimates of blood glucose in mass screening for diabetes.

, 1966
Kelly M West, Julie Stein, Tina Sanders
openalex   +2 more sources